Synovial Sarcoma: From Genetics to Genetic-based Animal Modeling
- 18 June 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Orthopaedics and Related Research
- Vol. 466 (9), 2156-2167
- https://doi.org/10.1007/s11999-008-0340-2
Abstract
Synovial sarcomas are highly aggressive mesenchymal cancers that show modest response to conventional cytotoxic chemotherapy, suggesting a definite need for improved biotargeted agents. Progress has been hampered by the lack of insight into pathogenesis of this deadly disease. The presence of a specific diagnostic t(X;18) translocation leading to expression of the unique SYT-SSX fusion protein in effectively all cases of synovial sarcoma suggests a role in the etiology. Other nonspecific anomalies such as overexpression of Bcl-2, HER-2/neu, and EGFR have been reported, but their role in the pathogenesis remains unclear. Using gene targeting, we recently generated mice conditionally expressing the human SYT-SSX2 fusion gene from mouse endogenous ROSA26 promoter in chosen tissue types in the presence of Cre recombinase. These mice develop synovial sarcoma when SYT-SSX2 is expressed within myoblasts, thereby identifying a source of this enigmatic tumor and establishing a mouse model of this disease that recapitulates the clinical, histologic, immunohistochemical, and transcriptional profile of human synovial sarcomas. We review the genetics of synovial sarcoma and discuss the usefulness of genetics-based mouse models as a valuable research tool in the hunt for key molecular determinants of this lethal disease as well as a preclinical platform for designing and evaluating novel treatment strategies.Keywords
This publication has 88 references indexed in Scilit:
- The Synovial Sarcoma SYT-SSX2 Oncogene Remodels the Cytoskeleton through Activation of the Ephrin PathwayMolecular Biology of the Cell, 2007
- Adaptor Molecule Crk Is Required for Sustained Phosphorylation of Grb2-Associated Binder 1 and Hepatocyte Growth Factor–Induced Cell Motility of Human Synovial Sarcoma Cell LinesMolecular Cancer Research, 2006
- Gene expression profiles relate to SS18/SSX fusion type in synovial sarcomaInternational Journal of Cancer, 2005
- Gene targeting in mice: functional analysis of the mammalian genome for the twenty-first centuryNature Reviews Genetics, 2005
- Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor β Tyrosine Kinase Receptors in Synovial SarcomaClinical Cancer Research, 2004
- Molecular characterisation of soft tissue tumours: a gene expression studyThe Lancet, 2002
- A KRAB-related domain and a novel transcription repression domain in proteins encoded by SSX genes that are disrupted in human sarcomasOncogene, 1998
- SYT–SSXGene Fusion as a Determinant of Morphology and Prognosis in Synovial SarcomaNew England Journal of Medicine, 1998
- Synovial sarcoma outcome following conservation surgery and radiotherapyRadiotherapy and Oncology, 1994
- SH2 and SH3 domains: From structure to functionCell, 1992